05.04.18
With a new structure in place, Lonza executives are optimistic about growth opportunities in 2018. As of January 1, the Specialty Ingredients segment began operating in three distinct units: a Consumer Health division, a Consumer & Resources Protection division and a Water Care business unit. The new Consumer Health division addresses the fast-moving consumer goods markets in nutrition, hygiene and personal care. The new Consumer & Resources Protection division addresses the coatings, composites and agricultural markets.
“Lonza confirms ongoing strong momentum for its businesses along the healthcare continuum and is confident to achieve a positive half-year result 2018,” the company said without giving detailed financial figures. “The strong business momentum also makes Lonza fully confident of achieving, at a minimum, the previously communicated full-year guidance of mid-single-digit sales growth on a comparable basis in line with mid-term guidance 2022 and 100 (basis point) improvement in core EBITDA margin in line with mid-term guidance 2022,” it added.
Lonza Consumer Health is showing good momentum across capsules and ingredients. In particular, two leading actives – UCII ingredient for joint health and Carnipure ingredient in sports nutrition – are benefiting from high demand. Growth in capsules and dosage forms is especially driven by clean-label specialty polymer solutions. In Q1 combined offerings continued to attract interest, fueled by more than 30 new dietary supplement product concept launches that join Lonza’s specialty ingredients and former Capsugel's innovative dosage forms. Additional growth momentum is expected due to synergistic geographic expansion across all businesses.
Disinfecting solutions in home and institutional hygiene applications saw continuous growth, driven by increased demand in North America and Europe that resulted from innovations to address regulatory compliance, according to the company.
“Lonza confirms ongoing strong momentum for its businesses along the healthcare continuum and is confident to achieve a positive half-year result 2018,” the company said without giving detailed financial figures. “The strong business momentum also makes Lonza fully confident of achieving, at a minimum, the previously communicated full-year guidance of mid-single-digit sales growth on a comparable basis in line with mid-term guidance 2022 and 100 (basis point) improvement in core EBITDA margin in line with mid-term guidance 2022,” it added.
Lonza Consumer Health is showing good momentum across capsules and ingredients. In particular, two leading actives – UCII ingredient for joint health and Carnipure ingredient in sports nutrition – are benefiting from high demand. Growth in capsules and dosage forms is especially driven by clean-label specialty polymer solutions. In Q1 combined offerings continued to attract interest, fueled by more than 30 new dietary supplement product concept launches that join Lonza’s specialty ingredients and former Capsugel's innovative dosage forms. Additional growth momentum is expected due to synergistic geographic expansion across all businesses.
Disinfecting solutions in home and institutional hygiene applications saw continuous growth, driven by increased demand in North America and Europe that resulted from innovations to address regulatory compliance, according to the company.